Manipal Health Enterprises
MANIPALHOSNSE

Manipal Health Enterprises

₹707.60-9.75 (1.36%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
705.70
Today’s high
721.90
52 week low
625.45
52 week high
815.00
Open price
720.00
Previous close
717.35
Live volume
2,68,555
Lower circuit
573.90
Upper circuit
860.80

Fundamentals

Market Cap
₹94,201Cr
ROE
10.59%
P/E Ratio(TTM)
103.94
EPS(TTM)
6.89
P/B Ratio
5.73
Dividend Yield
0.00%
Industry P/E
67.99
Book Value
124.89
Debt to Equity
1.53
Face Value
2

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹3,165
+8.48%
Profit (Cr)
₹243
+30.50%
08001.6k2.4k3.2k
Jun '25
Mar '26
Jun '26
Revenue growthValue
3Y CAGR+29%
Profit growthValue
3Y CAGR+29%

About

CEO/MD
Dilip Jose Puthiyidathu
Founded in
2010
NSE symbol
MANIPALHOS

Shareholding pattern

Mar '26
Jul '26
Aug '26
Shareholder details

Mutual Funds Invested (4)

Livesquawk
Goldman Sachs initiates Buy on Manipal Hospitals with ₹865 target, citing >20% topline CAGR and industry-leading margins. Growth driven by new-hospital ramp-ups, improved business mix, operating leverage, and turnaround of acquired hospitals.
Livesquawk
JPMorgan rates Manipal Hospitals Neutral; target price set at ₹800 citing steady volumes and ARPOB growth. Low return ratios, Sahyadri integration, and 27x/22x FY28/29 EV/EBITDA valuations limit near-term upside.
Livesquawk
HSBC initiates buy on Manipal Health with ₹1,000 target, citing profit growth 3X FY26-29E. Factors include doubled hospital beds since FY23, margin gains, and debt reduction to 0.7X by FY27E.
Livesquawk
Manipal Health Q1 net profit drops to ₹2.32B vs ₹2.5B YoY. Revenue rises to ₹30.91B, EBITDA up to ₹7.36B; margin slips to 23.8%.
2026
20
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks